Key statistics
As of last trade, Monopar Therapeutics Inc (1IY0:FRA) traded at 48.40, 95.16% above the 52 week low of 24.80 set on Apr 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 49.00 |
|---|---|
| High | 49.00 |
| Low | 48.40 |
| Bid | 49.20 |
| Offer | 52.50 |
| Previous close | 46.60 |
| Average volume | 27.33 |
|---|---|
| Shares outstanding | 6.68m |
| Free float | 5.23m |
| P/E (TTM) | -- |
| Market cap | 381.38m USD |
| EPS (TTM) | -3.44 USD |
Data delayed at least 15 minutes, as of Feb 12 2026 14:25 GMT.
More ▼
Announcements
- Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
- Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025
- Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
- Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
- Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients
- Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting
- Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting
- Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
- Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers
- Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
More ▼
